Document Detail

The effect of body temperature on myocardial protection conferred by ischaemic preconditioning or the selective adenosine A1 receptor agonist GR79236, in an anaesthetized rabbit model of myocardial ischaemia and reperfusion.
MedLine Citation:
PMID:  10510449     Owner:  NLM     Status:  MEDLINE    
1 The cardioprotective effect of N-[(1S, trans)-2-hydroxycyclopentyl]adenosine (GR79236), an adenosine A1 receptor agonist, was compared with that produced by ischaemic preconditioning in an anaesthetized rabbit model of myocardial ischaemia and reperfusion. In addition, we examined the effect of different body core temperatures on GR79236- or ischaemic preconditioning-induced cardioprotection when administered prior to ischaemia, and on cardioprotection induced by GR79236 administered 10 min prior to the onset of reperfusion. 2 When rabbits were subjected to 30 min occlusion of the left coronary artery, followed by 2 h reperfusion, GR79236 (3 x 10(-8) mol kg-1 i.v. (10.5 microg kg-1 i.v.)) or ischaemic preconditioning (5 min ischaemia followed by 5 min reperfusion), administered or applied 10 min prior to the occlusion, significantly limited the development of infarction. The cardioprotective effect of ischaemic preconditioning was significantly greater than that seen after administration of GR79236. Pre-treatment with the selective adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, 3.3 x 10(-6) mol kg-1 (1 mg kg-1 i.v.)), prevented the cardioprotective effect of GR79236, but not that of ischaemic preconditioning. 3 Maintaining body core temperature at 38.5 degrees C rather than at 37.0 degrees C did not influence infarct size in control groups of rabbits, but reduced the cardioprotective effect of GR79236 when administered 10 min prior to occlusion or 10 min prior to the onset of reperfusion. The cardioprotective effect of ischaemic preconditioning was not temperature-dependent. 4 In conclusion, myocardial protection conferred by GR79236 in anaesthetized rabbits is mediated via adenosine A1 receptors. Myocardial protection can be conferred when GR79236 is administered before the onset of ischaemia or reperfusion, and is reduced when body core temperature is maintained at 38.5 degrees C rather than at 37.0 degrees C. In contrast, myocardial protection conferred by ischaemic preconditioning is not reduced by adenosine A1 receptor blockade, or by maintaining body core temperature at 38.5 degrees C rather than at 37.0 degrees C. These findings point to distinct differences in the mechanisms of induction of myocardial protection by adenosine A1 receptor agonist and ischaemic preconditioning. They also highlight the need for careful control of body core temperature when investigating the phenomenon of cardioprotection.
A Sheldrick; K M Gray; G M Drew; J B Louttit
Related Documents :
6350399 - Role of cellular proteinases in acute myocardial infarction. i. proteolysis in nonische...
8595609 - Effect of catecholamine depletion on myocardial infarct size in dogs: role of catechola...
8640599 - An irreversible a1-selective adenosine agonist preconditions rabbit heart.
9562019 - Lack of adenosine causes myocardial refractoriness.
15623429 - Administration of a co-releasing molecule induces late preconditioning against myocardi...
8071859 - Role of bradykinin in myocardial preconditioning.
11078229 - Benefit of coronary reperfusion before intervention on outcomes after primary angioplas...
15056839 - Left ventricular mobile thrombus associated with ventricular assist device: diagnosis b...
3465579 - The use of digitalis in patients with chronic respiratory failure.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  British journal of pharmacology     Volume:  128     ISSN:  0007-1188     ISO Abbreviation:  Br. J. Pharmacol.     Publication Date:  1999 Sep 
Date Detail:
Created Date:  2000-01-04     Completed Date:  2000-01-04     Revised Date:  2013-06-11    
Medline Journal Info:
Nlm Unique ID:  7502536     Medline TA:  Br J Pharmacol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  385-95     Citation Subset:  IM    
Systems Biology Unit, Glaxo Wellcome Research and Development, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenosine / analogs & derivatives*,  pharmacology
Blood Pressure / drug effects
Body Temperature / physiology*
Heart Rate / drug effects
Ischemic Preconditioning, Myocardial*
Myocardial Infarction / pathology,  prevention & control
Myocardial Ischemia / pathology*,  physiopathology
Myocardial Reperfusion Injury / pathology,  prevention & control*
Purinergic P1 Receptor Agonists*
Xanthines / pharmacology
Reg. No./Substance:
0/Purinergic P1 Receptor Agonists; 0/Xanthines; 102146-07-6/1,3-dipropyl-8-cyclopentylxanthine; 124555-18-6/N-((1S,trans)-2-hydroxycyclopentyl)adenosine; 58-61-7/Adenosine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Curcumin inhibits Th1 cytokine profile in CD4+ T cells by suppressing interleukin-12 production in m...
Next Document:  Functional expression of a cDNA encoding a human ecto-ATPase.